2029 Biosimilars Drug Development Drugs 
Vial
MARCH 1, 2024
Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market. billion by 2029. By revenue, the largest CRO in the US was Thermo Fisher Scientific Inc.,
Drug Discovery World
JULY 26, 2024
This, coupled with looming patent expirations, the impact of new drug pricing regulations, and tighter universal regulation of medical devices presents a complex environment for both large and small life science companies. Despite criticising the IRA in the past, Trump is also prioritising a reduction in drug costs.
Expert insights. Personalized for you.
52 
Let's personalize your content